| 1 |
34325497 |
10.4143/crt.2021.752 |
2022 |
Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. |
MYD88 |
| 2 |
34411492 |
10.1139/cjpp-2021-0007 |
2022 |
Colchicine attenuates renal ischemia-reperfusion-induced liver damage: implication of TLR4/NF-κB, TGF-β, and <i>BAX</i> and <i>Bcl-2</i> gene expression. |
MYD88 |
| 3 |
34448823 |
10.1182/bloodadvances.2021004212 |
2022 |
The molecular hallmarks of primary and secondary vitreoretinal lymphoma. |
MYD88 |
| 4 |
34638136 |
10.1182/bloodadvances.2020003698 |
2022 |
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. |
MYD88 |
| 5 |
34654055 |
10.1182/bloodadvances.2021006034 |
2022 |
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. |
MYD88 |
| 6 |
34802044 |
10.1038/s41379-021-00954-z |
2022 |
A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform. |
MYD88 |
| 7 |
35020191 |
10.1111/bjh.18036 |
2022 |
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. |
MYD88 |
| 8 |
35028710 |
10.1007/s00428-021-03265-5 |
2022 |
Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas. |
MYD88 |
| 9 |
35030632 |
10.1182/bloodadvances.2021006410 |
2022 |
Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. |
MYD88 |
| 10 |
35044826 |
10.1126/sciadv.abl4644 |
2022 |
Preneoplastic somatic mutations including <i>MYD88</i><sup>L265P</sup> in lymphoplasmacytic lymphoma. |
MYD88 |
| 11 |
35096069 |
10.1155/2022/1182384 |
2022 |
Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia). |
MYD88 |
| 12 |
35106936 |
10.1002/cam4.4550 |
2022 |
SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups. |
MYD88 |
| 13 |
35126963 |
10.1177/20406207211072839 |
2022 |
MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. |
MYD88 |
| 14 |
35142151 |
10.3324/haematol.2021.279908 |
2022 |
A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas. |
MYD88 |
| 15 |
35149375 |
10.1016/j.ctarc.2022.100527 |
2022 |
Current approach to Waldenström Macroglobulinemia. |
MYD88 |
| 16 |
35169086 |
10.11477/mf.1436204531 |
2022 |
[Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma]. |
MYD88 |
| 17 |
35210172 |
10.1016/j.preteyeres.2022.101053 |
2022 |
Challenges in the diagnosis and management of vitreoretinal lymphoma - Clinical and basic approaches. |
MYD88 |
| 18 |
35223507 |
10.3389/fonc.2022.824632 |
2022 |
<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS. |
MYD88 |
| 19 |
35236331 |
10.1186/s12885-022-09237-5 |
2022 |
Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma. |
MYD88 |
| 20 |
35255429 |
10.1016/j.anndiagpath.2021.151886 |
2022 |
De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients. |
MYD88 |
| 21 |
35255496 |
10.1182/bloodadvances.2021006147 |
2022 |
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. |
MYD88 |
| 22 |
35300216 |
10.2147/JIR.S341355 |
2022 |
The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma. |
MYD88 |
| 23 |
35339405 |
10.1016/j.clml.2022.02.005 |
2022 |
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. |
MYD88 |
| 24 |
35359040 |
10.3760/cma.j.cn112151-20211220-00915 |
2022 |
[Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma]. |
MYD88 |
| 25 |
35401516 |
10.3389/fimmu.2022.842439 |
2022 |
Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma. |
MYD88 |
| 26 |
35454017 |
10.3390/diagnostics12040969 |
2022 |
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance. |
MYD88 |
| 27 |
35510210 |
10.1177/20406207221093962 |
2022 |
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond. |
MYD88 |
| 28 |
35538064 |
10.1038/s41467-022-30050-y |
2022 |
The genomic and transcriptional landscape of primary central nervous system lymphoma. |
MYD88 |
| 29 |
35554927 |
10.1002/eji.202149746 |
2022 |
Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas. |
MYD88 |
| 30 |
35628381 |
10.3390/ijms23105570 |
2022 |
<i>MYD88</i> Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. |
MYD88 |
| 31 |
35646048 |
10.3389/fgene.2022.878618 |
2022 |
Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. |
MYD88 |
| 32 |
35759728 |
10.1182/blood.2022015926 |
2022 |
Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma. |
MYD88 |
| 33 |
35877223 |
10.3390/curroncol29070363 |
2022 |
Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation. |
MYD88 |
| 34 |
35879731 |
10.1186/s40364-022-00401-4 |
2022 |
Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma. |
MYD88 |
| 35 |
35928872 |
10.3389/fonc.2022.932674 |
2022 |
Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma. |
MYD88 |
| 36 |
35937947 |
10.1155/2022/6441139 |
2022 |
Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis. |
MYD88 |
| 37 |
35968590 |
10.3760/cma.j.issn.0253-2727.2022.06.006 |
2022 |
[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review]. |
MYD88 |
| 38 |
35973369 |
10.1016/j.intimp.2022.109138 |
2022 |
Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization. |
MYD88 |
| 39 |
36006771 |
10.1097/PAS.0000000000001957 |
2022 |
Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Multicenter Collaborative Study. |
MYD88 |
| 40 |
36051079 |
10.1002/jha2.428 |
2022 |
Targetable alterations in primary extranodal diffuse large B-cell lymphoma. |
MYD88 |
| 41 |
36055572 |
10.1016/j.clim.2022.109105 |
2022 |
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. |
MYD88 |
| 42 |
36059608 |
10.3389/fonc.2022.955080 |
2022 |
Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis. |
MYD88 |
| 43 |
36081566 |
10.3389/fonc.2022.941347 |
2022 |
Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx. |
MYD88 |
| 44 |
32139889 |
10.1038/s41375-020-0766-4 |
2021 |
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. |
MYD88 |
| 45 |
32583848 |
10.1093/neuonc/noaa145 |
2021 |
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. |
MYD88 |
| 46 |
32810857 |
10.1159/000509286 |
2021 |
Current and Emerging Treatments for Waldenström Macroglobulinemia. |
MYD88 |
| 47 |
32973328 |
10.1038/s41379-020-00685-7 |
2021 |
The clinicopathological and molecular features of sinusoidal large B-cell lymphoma. |
MYD88 |
| 48 |
33202420 |
10.1182/blood.2020008520 |
2021 |
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. |
MYD88 |
| 49 |
33232972 |
10.1182/blood.2020005244 |
2021 |
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. |
MYD88 |
| 50 |
33263441 |
10.1080/17474086.2021.1856652 |
2021 |
Development of molecular intervention strategies for B-cell lymphoma. |
MYD88 |
| 51 |
33311649 |
10.1038/s41379-020-00720-7 |
2021 |
Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. |
MYD88 |
| 52 |
33395752 |
10.1016/j.tranon.2020.100977 |
2021 |
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. |
MYD88 |
| 53 |
33512416 |
10.1182/blood.2020007245 |
2021 |
Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. |
MYD88 |
| 54 |
33581493 |
10.1016/j.ctarc.2021.100310 |
2021 |
Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients. |
MYD88 |
| 55 |
33685720 |
10.1016/j.pathol.2021.01.002 |
2021 |
New developments in non-Hodgkin lymphoid malignancies. |
MYD88 |
| 56 |
33735664 |
10.1016/j.neo.2021.02.002 |
2021 |
Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. |
MYD88 |
| 57 |
33735913 |
10.1182/blood.2020010137 |
2021 |
A rapid genotyping panel for detection of primary central nervous system lymphoma. |
MYD88 |
| 58 |
33747936 |
10.3389/fonc.2021.622648 |
2021 |
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. |
MYD88 |
| 59 |
33777778 |
10.3389/fonc.2021.628807 |
2021 |
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. |
MYD88 |
| 60 |
33899787 |
10.1097/PAS.0000000000001691 |
2021 |
The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma. |
MYD88 |
| 61 |
34132782 |
10.1182/blood.2021011405 |
2021 |
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. |
MYD88 |
| 62 |
34204385 |
10.3390/cancers13123032 |
2021 |
Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing. |
MYD88 |
| 63 |
34236648 |
10.1007/978-1-0716-1669-7_20 |
2021 |
Generation and Surgical Analysis of Genetic Mouse Models to Study NF-κB-Driven Pathogenesis of Diffuse Large B Cell Lymphoma. |
MYD88 |
| 64 |
34254378 |
10.1111/neup.12739 |
2021 |
Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six cases. |
MYD88 |
| 65 |
34327781 |
10.1111/cas.15091 |
2021 |
Current progress and future perspectives of research on intravascular large B-cell lymphoma. |
MYD88 |
| 66 |
34330762 |
10.1136/jitc-2021-002410 |
2021 |
High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies. |
MYD88 |
| 67 |
34378195 |
10.1111/bjh.17765 |
2021 |
Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort. |
MYD88 |
| 68 |
34405609 |
10.3760/cma.j.cn112151-20210110-00023 |
2021 |
[Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation]. |
MYD88 |
| 69 |
34497201 |
10.11406/rinketsu.62.1139 |
2021 |
[Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan]. |
MYD88 |
| 70 |
34570179 |
10.1182/bloodadvances.2021004668 |
2021 |
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. |
MYD88 |
| 71 |
34606736 |
10.1080/14728222.2021.1988927 |
2021 |
Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma. |
MYD88 |
| 72 |
34651869 |
10.1002/hon.2933 |
2021 |
The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma. |
MYD88 |
| 73 |
34657049 |
NA |
2021 |
[Circulating Tumor DNA Analysis in Lymphomas]. |
MYD88 |
| 74 |
34706861 |
10.1136/bjophthalmol-2021-319580 |
2021 |
Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma. |
MYD88 |
| 75 |
34739844 |
10.1016/j.ccell.2021.10.006 |
2021 |
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. |
MYD88 |
| 76 |
34925435 |
10.3389/fgene.2021.677650 |
2021 |
Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing. |
MYD88 |
| 77 |
34944954 |
10.3390/cancers13246334 |
2021 |
Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System. |
MYD88 |
| 78 |
34945004 |
10.3390/cancers13246384 |
2021 |
Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel. |
MYD88 |
| 79 |
35087759 |
10.3389/fonc.2021.801124 |
2021 |
Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia. |
MYD88 |
| 80 |
35116576 |
10.21037/tcr-20-2525 |
2021 |
Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database. |
MYD88 |
| 81 |
29629945 |
10.1097/PAI.0000000000000655 |
2020 |
Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. |
MYD88 |
| 82 |
31123031 |
10.3324/haematol.2018.214122 |
2020 |
<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. |
MYD88 |
| 83 |
31609782 |
10.1097/PAS.0000000000001386 |
2020 |
Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma. |
MYD88 |
| 84 |
31738823 |
10.1182/blood.2019002699 |
2020 |
Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. |
MYD88 |
| 85 |
31863183 |
10.1007/s00428-019-02698-3 |
2020 |
Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. |
MYD88 |
| 86 |
31886867 |
10.1093/jnen/nlz125 |
2020 |
Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma. |
MYD88 |
| 87 |
31902622 |
10.1016/j.pathol.2019.11.002 |
2020 |
A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. |
MYD88 |
| 88 |
31960730 |
10.1080/10428194.2020.1711901 |
2020 |
Waldenstrom's macroglobulinemia in the era of immunotherapy. |
MYD88 |
| 89 |
31964218 |
10.1177/1078155219895079 |
2020 |
Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level. |
MYD88 |
| 90 |
31992103 |
10.1080/10428194.2020.1719100 |
2020 |
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. |
MYD88 |
| 91 |
32005797 |
10.1038/s41408-020-0277-6 |
2020 |
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. |
MYD88 |
| 92 |
32012328 |
10.1002/hon.2718 |
2020 |
High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas. |
MYD88 |
| 93 |
32014679 |
10.1016/j.ejmech.2020.112092 |
2020 |
Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. |
MYD88 |
| 94 |
32056332 |
10.1111/cas.14347 |
2020 |
Gene expression profiling of primary vitreoretinal lymphoma. |
MYD88 |
| 95 |
32083995 |
10.1200/JCO.19.02314 |
2020 |
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. |
MYD88 |
| 96 |
32127472 |
10.1073/pnas.1921187117 |
2020 |
Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14. |
MYD88 |
| 97 |
32161170 |
10.1128/JVI.02123-19 |
2020 |
Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma. |
MYD88 |
| 98 |
32201861 |
10.1093/noajnl/vdaa018 |
2020 |
Primary CNS lymphoma commonly expresses immune response biomarkers. |
MYD88 |
| 99 |
32239385 |
10.1007/s11523-020-00710-4 |
2020 |
Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib. |
MYD88 |
| 100 |
32322395 |
10.1186/s40364-020-00189-1 |
2020 |
TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients. |
MYD88 |
Datasets
Models
